MICROBOT MEDICAL INC
MBOTNASDAQTrading Snapshot
- Day Range
- $1.23 – $1.25
- 52-Week Range
- $1.26 – $3.47
- Volume
- $2.00B
- Avg Volume
- $2.39B
- Shares Outstanding
- 67.2M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $339,269
- Last Q Revenue
- $241,000
- P/E Ratio
- —
- P/S Ratio
- 247.5x
- EPS (TTM)
- $-0.26
- Dividend Yield
- —
- Dilution (1yr)
- +294.6%
Why Investors Own MBOT
- ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 42% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MICROBOT MEDICAL INC
MBOT
StockOtter · stockotter.spaceAbout MICROBOT MEDICAL INC
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Microbot Medical® Highlights Growth Strategy
Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
Financial Analysis: Koninklijke Philips (NYSE:PHG) & Microbot Medical (NASDAQ:MBOT)
Koninklijke Philips (NYSE: PHG - Get Free Report) and Microbot Medical (NASDAQ: MBOT - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April T
New Strong Buy Stocks for July 23rd
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year's Society of Ro